DRUG
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
Status
Terminated
Phase
Phase 2
Enrollment
101
Locations
48
Results
Posted
Publications
1
Study summary
What the protocol is testing.
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients age 7-11 will receive oral liquid or oral solid capsule and patients 12-17 will receive solid oral capsule formulation. Children ages 7-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of IBS-C.
Interventions
Treatment arms and agents.
DRUG
Linaclotide Dose B
DRUG
Linaclotide Dose C
DRUG
Linaclotide Approved Adult Dose
DRUG
Matching Placebo
Timeline
From registration to results.
First posted
Sep 24, 2015
Study start
Nov 1, 2015
Primary completion
Aug 30, 2019
Study completion
Aug 30, 2019
Results posted
Dec 28, 2020
Registry updated
Dec 28, 2020
Outcomes
What the study measures.
Primary outcomes
Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Treatment Period
Time frame · Baseline (14 days prior to randomization and up to randomization) to week 4
SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. SBM rate was defined as SBMs/week during the 4-week Treatment period. Participants recorded the occurrence of BMs and use of rescue medication, morning and evening, daily in an eDiary since pretreatment period. The SBM frequency rate (SBMs/week) during the analysis period for each participant were calculated as \[(total number of SBMs in the analysis period/number of days in the analysis period)\*7\]. Baseline value was based on values collected 14 days before randomization up to randomization. Change from Baseline was calculated as the SBM frequency rate during the 4-week treatment period - SBM frequency rate at baseline. A positive change from Baseline indicates improvement.
Secondary outcomes
Change From Baseline in 4-week Abdominal Pain Daytime Symptoms Based on Evening Assessment of Abdominal Pain Symptoms
Time frame · Baseline (14 days prior to randomization) to week 4
The abdominal pain score was measured using 5-point scale. Participants answered the questions, How much did your tummy hurt as: 0=none, 1=a tiny bit, 2=a little, 3=some, and 4=a lot. The 4-week daytime abdominal pain was calculated as the average of nonmissing scores in evening eDiary during the Treatment Period with higher value indicating greater symptom severity. Baseline value was the average of non-missing values collected 14 days before randomization. Change from Baseline was calculated as the daytime abdominal pain score during the 4-week treatment period (i.e. average of non-missing daytime scores during 4-week treatment period) - daytime abdominal pain score at baseline. A negative change from Baseline indicates improvement.
Change From Baseline in 4-week Stool Consistency
Time frame · Baseline (14 days prior to randomization and up to randomization) to week 4
Participants used 7-point pediatric Bristol Stool Form (p-BSFS) scale to rate stool consistency for each BM in morning and evening eDiary where 1=small hard lumps or balls like pebbles,2=fat sausage shape but lumpy and hard,3=a sausage but with cracks on it,4=sausage or snake, smooth and soft,5=chicken nuggets, soft smooth blobs,6=oatmeal, fluffy mushy pieces,7=milkshake, watery. Scores in 4-week treatment period were calculated as mean of participants non-missing, SBM associated p-BSFS scores during 4-week treatment period. Baseline value was based on values collected 14 days before randomization up to randomization.
Change From Baseline in 4-week Severity of Straining
Time frame · Baseline (14 days prior to randomization and up to randomization) to week 4
Severity of straining was scored on 5-point scale for question-When you pooped, how hard did you push? The score ranges from 0= not hard at all,1= I pushed a tiny bit hard,2= I pushed a little hard,3= I pushed hard,4= I pushed very hard with higher scores indicating more severe straining. Participants recorded degree of straining for each BM in morning and evening eDiary. Scores during 4-week treatment period were calculated as mean of participant's non-missing, SBM associated straining scores during 4-week treatment period.
Change From Baseline in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment
Time frame · Baseline (14 days prior to randomization) to week 4
Participants recorded their assessment of abdominal bloating in the evening eDiary. Participants answered the question: How big and full did your tummy feel? on a scale, where: 0=none, 1=a tiny bit, 2=a little, 3=medium or 4=very, with a higher score indicating more severe bloating. Baseline value was the average of values collected 14 days before randomization. The 4-week daytime abdominal bloating symptoms were calculated as the average of non-missing scores reported in the evening eDiary during the treatment period. Change from Baseline was calculated as the 4-week daytime abdominal bloating score during the treatment period - daytime abdominal bloating score at baseline. A negative change from Baseline indicates improvement.
Change From Baseline in 4-week Overall Complete Spontaneous Bowel Movement (CSBM) Frequency Rate (CSBMs Per Week)
Time frame · Baseline (14 days prior to randomization and up to randomization) to week 4
SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. A CSBM was an SBM that was associated with a sense of complete evacuation. Participants recorded their assessment of the sensation of incomplete evacuation for each BM in the morning and evening eDiary. The 4-week overall CSBM frequency rate was calculated as \[total number of CSBMs in the analysis period/number of days in the analysis period\]\*7). Baseline value was based on values collected 14 days before randomization and up to randomization. Change from Baseline was calculated as the CSBM frequency rate during the 4-week treatment period - CSBM frequency rate at baseline. A positive change from Baseline indicates improvement.
Eligibility
Who can take part.
- Minimum age
- 7 Years
- Maximum age
- 17 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Patient weighs at least 18 kg (39.7 lbs) * Patient meets Rome III criteria for child/adolescent IBS: at least once per week for at least 2 months before Screening Visit, the patient experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time: * a) Improvement with defecation * b) Onset associated with a change in frequency of stool * c) Onset associated with a change in form (appearance) of stool * Patient meets modified Rome III criteria for child/adolescent Functional Constipation (FC): For at least 2 months before the Screening Visit, the patient has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, patient meets 1 or more of the following: * a) History of retentive posturing or excessive volitional stool retention * b) History of painful or hard bowel movements (BMs) * c) Presence of a large fecal mass in the rectum * d) History of large diameter stools that may obstruct the toilet * Patient is willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine * Patient has an average of fewer than 3 spontaneous BMs (SBMs) per week during the 14 days before the randomization day and up to the randomization. An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM * Patient or parent/guardian/LAR or caregiver is compliant with eDiary by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit Exclusion Criteria: * Patient reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale \[p-BSFS\]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization * Select medical history or conditions that may be related to other causes of constipation or may interfere with safety and efficacy analyses * Patient has required manual disimpaction anytime prior to randomization or disimpaction during in-patient hospitalization within one year prior to randomization * Patient is unable to tolerate the placebo during rhe Screening Period
Study locations
48 registered sites.
Canada · United States. Showing up to 24 locations stored in the fast local snapshot.
HealthStar Research, LLC
Hot Springs, Arkansas, United States
Applied Research Center of Arkansas
Little Rock, Arkansas, United States
Advanced Research Center - Site 069
Anaheim, California, United States
Kindred Medical Institute for Clinical Trials, LLC
Corona, California, United States
WCCT Global, LLC
Costa Mesa, California, United States
ACTCA, Inc
Los Angeles, California, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Center for Clinical Trials, LLC
Paramount, California, United States
University of California at San Francisco
San Francisco, California, United States
Advanced Medical Research Center
Miami, Florida, United States
Children's Center for Digestive Health Care LLC
Atlanta, Georgia, United States
Sleepcare Clinical Research Institute
Stockbridge, Georgia, United States
Methodist Medical Center
Peoria, Illinois, United States
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, United States
Heartland Research Associates, LLC
Wichita, Kansas, United States
Willis-Knighton Physician Network
Shreveport, Louisiana, United States
Certified Research Consultants Virgo/Carter Pediatrics
Silver Spring, Maryland, United States
GI Associates and Endoscopy Center
Jackson, Mississippi, United States
Children's Mercy Hospital
Kansas City, Missouri, United States
Boys Town National Research Hospital
Boys Town, Nebraska, United States
Midwest Children Health Research Institute
Lincoln, Nebraska, United States
Midwest Children Health Research Institute
Lincoln, Nebraska, United States
Goryeb Children's Hospital
Morristown, New Jersey, United States
Columbia University Medical Center and Morgan Stanley Children's Hospital of New York
New York, New York, United States
Publications
Results and literature.
Related trials
More studies on Linaclotide.
A Study of Virtual Reality and Linaclotide for IBS-C
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
"Efficacy and Safety of Linaclotide in Chronic Constipation"
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
Linaclotide for Colonoscopy Bowel Prep
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.